$XTALPI(02228.HK)
Short selling data this morning: 02228 Pharmaron (Beijing) Co., Ltd.-P 705,000 5,143,150. Average selling price 7.29
I expect the closing price to be above this level.
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, th...
Pharmaron (3759.HK) reversed early gains, opening at the 30.10 HKD session high before sliding to a 28.10 HKD close, down 5.89%, after touching 28.04 HKD at 14:51 BJ; full-day turnover was 471.7 million HKD on a 1.32% turnover rate. The retreat came despite a constructive broker backdrop: Goldman Sachs flagged strong third-quarter orders across China CRO/CDMO names that improve 2027 visibility, while JPMorgan initiated coverage with an overweight rating and Morgan Stanley stayed positive. Fundamentals also looked firm, with Q3 revenue of 5.16 billion HKD up 29.45% year on year, operating profit up 33.81% and EPS up 16.55%, leaving the shares at 25.0x PE and 2.63x PB. Even so, the stock is still up 41.7% year to date, sitting above its MA20 of 27.89 HKD but below MA60 of 29.29 HKD and 19.39% below the 52-week high of 34.86 HKD. Though proposed US COINS Act curbs on China biotech investment and the overhang from the completed major shareholder stake sale keep sentiment fragile.
With JPMorgan lifting its stake by roughly 771,700 shares and initiating coverage of China's CDMO sector at Overweight, Pharmaron opened at HK$31.00, about 5.4% above the prior close of HK$29.40, then gave back to HK$29.76 by 10:14 BJ and consolidated between HK$30.02 and HK$30.42 through the afternoon, closing at HK$30.06 for a 2.24% gain on 4.09 million shares worth HK$124 million. Q3 2026 results echo the move: revenue of HK$5.157 billion rose 29.45% year on year, operating income of HK$781 million climbed 33.81%, net profit of HK$581 million gained 21.02%, EPS of HK$0.317 rose 16.55%, with ROE at 11.96% and net margin at 11.27%; the company also plans a US$10 million commitment to a fund focused on nucleic acid drugs and gene therapy. The stock is up 51.59% year to date, 108.03% above its June 9 low of HK$14.45, yet still 13.77% below the August 19 high of HK$34.86, holding above MA20 of 27.67 and MA60 of 29.40 at 26.76x PE and 2.82x PB. Though a 1.14% turnover rate and the fade from HK$31.00 suggest demand at that level remains to be tested.
Profit-taking after a steep run left Pharmaron opening lower, bottoming at 28.42 HKD at 09:32 BJ and recovering to 29.14, still down 4.14% on 318 million HKD turnover, with the session high of 29.42 printed at 09:45. The stock had earlier gained 12% in a single session, while a filing that actual controller Lou Xiaoqiang deferred the repurchase of 7.37 million pledged shares for funding needs weighed on sentiment; JPMorgan initiated coverage of Pharmaron and Asymchem H-shares at Overweight, Morgan Stanley and BOCOM International reiterated Buy, the latter flagging re-accelerating 3Q26 results. Third-quarter revenue rose 29.45% yoy to 5.16 billion HKD, operating profit up 33.81% to 781 million and net profit up 21.02% to 581 million, with EPS of 0.317 (+16.55%). The shares are up 46.95% year-to-date, 16.41% below the 34.86 52-week high, above the 27.757 MA20 yet just under the 29.408 MA60, at 25.94x PE and 2.73x PB. Though net profit growth of 21.02% still trails revenue growth of 29.45%.
Pharmaron (3759.HK) rose 3.5% to HK$30.40 in a spike-and-fade session, touching HK$31.48 at 09:58 BJ before easing into a HK$30.20-31.10 afternoon band on HK$474m turnover. China Post Securities flagged pharma valuations at historically low levels and Guosen Securities data showed mutual funds added CXO positions in Q3, while BOCOM International reiterated Buy after 3Q26 results and Morgan Stanley kept its Buy rating, driving the morning push. Q3 revenue reached HK$5.16bn, up 29.45% YoY, operating profit HK$781m up 33.81% and net profit HK$581m up 21.02%, lifting net margin to 11.27%, so fundamentals and sector fund flows pointed the same way. The stock is up 53.3% year to date and sits 12.79% below its 52-week high of HK$34.86 but above MA20 (HK$27.86) and MA60 (HK$29.41). Though the intraday peak did not hold after disclosure that actual controller Lou Xiaoqiang deferred repurchase of 7.37 million pledged shares on funding needs.
Pharmaron (3759.HK) opened flat and then rallied through the afternoon, closing up 12.99% at HK$29.38 on HK$233 million turnover, as accelerating third-quarter results coincided with a sector-wide bid for CRO names. It traded in a narrow HK$26.30-27.30 band during the morning session before climbing one-way from HK$27.14 to an intraday high of HK$29.50 at 15:25 BJ. Q3 revenue reached HK$5.157 billion, up 29.45% year on year, operating profit rose 33.81% and net profit of HK$581.4 million gained 21.02%; net margin recovered to 11.27% and new orders grew more than 30%, which BOCOM International cited while reiterating its Buy rating, while WuXi Bio rose over 4% as CRO concept stocks led gains. The shares are up 48.16% YTD yet still sit 15.72% below the 52-week high of HK$34.86 set on 19 August, having just reclaimed the MA20 of HK$27.95 and nearing the MA60 of HK$29.39, with PE at 26.15x. Though controller Lou Xiaoqiang deferred repurchase of 7.37 million pledged shares on funding needs, a countervailing factor to watch.
Weekly Recap | PHARMARON -4.42%, most brokers rate it buy
G Sachs: Strong 3Q Orders for China's CRO and CDMO Firms Enhance Visibility for 2027
Weekly Recap | PHARMARON +7.13%, most brokers rate it buy
JPM: China's CDMO Sector Enters New Development Phase; Initiates Overweight on PHARMARON and ASYMCHEM H Shrs
Pharmaron drops 6%
Hong Kong stocks opened high and moved higher, with technology stocks and pharmaceutical stocks rising together. The technology index rose 2.35%, Tencent Music surged more than 15% after earnings, and Alibaba rose more than 4%.
The three major Hong Kong stock indices collectively retreated. WuXi AppTec's performance ignited the CRO sector, while tech stocks faced pressure, dragging down the indices.
